Future Table of Contents

Future Table of Contents

Volume 25, Number 2 (April 2018)

Ataxia-Telangectasia gene Mutation heterozygosity in breast cancer: A narrative review
K.J. Jerzak, T. Mancuso, A. Eisen

Aromatase inhibitors in premenopausal women with breast cancer: review of state of art and future prospectives
M. Pistelli, A. Della Mora, Z. Ballatore, R. Berardi

Radiotherapy use in breast cancer patients undergoing mastectomy with or without reconstruction
T.A. Koulis, A. Dang, C. Speers, R.A. Olson

Intravenous vitamin C in the supportive care of cancer patients – a review and rational approach
E. Klimant, H.L. Wright, D. Rubin, D. Seely, M. Markman

Prescribing Practices of Endocrine Therapy for Ductal Carcinoma in Situ in British Columbia
A. Chaudhry

A new Assessment Algorithm Based on clinical data and computed tomography features for Diagnosing EGFR Mutation adenocarcinoma
Y. Cao

Male Oncology Research and Education (MORE) Program for men at high risk for prostate cancer
J. Lorentz

Perceptions of primary care providers on implementing breast cancer survivorship care
M. Luctkar-Flude, A. Aiken, M.A. McColl, J. Tranmer

Factors associated with imaging in early breast cancer patients following initial treatment
K. Enright, T. Desai, R. Sutradhar, A. Gonzalez, M. Powis, N. Taback, C.M. Booth, M.E. Trudeau, M.K. Krzyzanowska

Adherence and outcomes of a galactomannan screening protocol in high risk hematology patients
A.M. Bombassaro, S. Harricharan, K. Biederman, A. Lazo-Langner, S. Elsayed, A. Fulford, Johannes A. Delport, A. Xenocostas

Barriers to Participation in Clinical Trials: A Physician Survey
A. Mahmud, O. Zalay, A. Springer, K. Arts, E. Eisenhauer

Ductal Carcinoma in Situ is Presumably not a Metastatic Disease
B.T. Snodgrass

Pharmacological interventions for fatigue in cancer and transplant meta-analysis
D. Tomlinson, P.D. Robinson, S. Oberoi, D. Cataudella, N. Culos-Reed, H. Davis, N. Duong, F. Gibson, M. Götte, P. Hinds, S.L. Nijhof, P. van der Torre, S. Cabral, L.L.Dupuis, L. Sung

Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer
S. Chae

Variation in routine follow-up care after curative treatment of head and neck cancer: A population-based study in Ontario, Canada
K. Brennan, S. Hall, T. Owen, R. Griffiths, Y. Peng

Follow up
A. Beswick

Connecting People with Cancer to Physical Activity and Exercise Programs: A Pathway to Create Accessibility and Engagement
D. Santa Mina

Measuring patient-reported outcomes to improve cancer care in Canada: an analysis of provincial survey data
K. Tran

Evidence-based best practices for EGFR-T790M testing in lung cancer in Canada
T. Stockley, C. Souza, P. Cheema, B. Melosky, S. Kamel-Reid, M. Tsao, A. Spatz, A. Karsan

Upcoming in Current Oncology


Irreversible Tyrosine Kinase Inhibition of EGFR with Afatinib in EGFR mutation-positive Advanced Non-Small Cell Lung Cancer
S. Morin-Ben Abdallah, V. Hirsh

Brain Metastases in Non-Small Cell Lung Cancer: Are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
S. Morin-Ben Abdallah, A. Wong

Anti-angiogenic therapies in non small cell lung cancer
P.M. Ellis, A. Alshangiti, G. Chandhoke

Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
C.A. Butts

Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
A. AlFakeeh, C. Brezden-Masley

ALK inhibitors, resistance development, clinical trials
J. Rothenstein, N. Chooback

Circulating Tumour DNA in EGFR-mutant NSCLC: A Review
M. Cabanero, M. Tsao

Real-world patient and caregiver-reported outcomes in advanced breast cancer
V. Lambert-Obry, A.G. Laliberte, A. Castonguay, G. Zanotti, T. Tran, M. Mates, J. Lemieux, P. Chabot, C. Prady, F. Couture, J. Lachaine

An algorithm for treatment of squamous non-small cell lung cancer: an evidence-based overview
N. Daaboul, G. Nicholas, S.A. Laurie

Resistance developments to EGFR-TKIs, T790M and Clinical trials
G.M. O'Kane, T.A. Barnes, N.B. Leighl

Advanced Typical and Atypical Carcinoid Tumours of the Lung: Management Guidelines
B. Melosky

Clinical Application and Utility of Genomic Assays in Early Stage Breast Cancer: Key Lessons Learned to Date
S. Chia

Rapidly changing treatment algorithms for metastatic non-squamous NSCLC
B. Melosky

Elective Nodal Irradiation or Involved Field Irradiation in Definitive Chemo-radiotherapy of Esophageal Squamous Cell Cancer: A Retrospective Analysis in Clinical N0 Patients
M. Li

Optimising vascular access for patients receiving intravenous systemic therapy for early stage breast cancer – A survey of oncology nurses and physicians
N. Le Vasseur, C. Stober, K. Daigle, A. Robinson, S. McDiarmid, S. Mazzarello, B. Hutton, A. Joy, D. Fergusson, J. Hilton, M. McInnes, M. Clemons

Perceptions around vascular access for intravenous systemic therapy and risk factors for lymphedema in early stage breast cancer – A patient survey
N. LeVasseur, C. Stober, M. Ibrahim, S. Gertler, J. Hilton, A. Robinson, S. McDiarmid, D. Fergusson, S. Mazzarello, B. Hutton, A. Joy, M. McInnes, M. Clemons

Head and Neck Cancer Patients Undergoing Radiotherapy: A Bioimpedance Analysis
K. Singh Kohli

How can we better help cancer patients quit smoking? The London Regional Cancer Program experience with smoking cessation
S. M. Davidson, A.V. Louie, R.G. Boldt

Unnecessary variations in practice: how to improve cancer care through pragmatic trials
M. Clemons

Glove and Instrument Handling in Cancer Surgery: A Survey of Surgeons' Beliefs and Practices
D. Berger-Richardson, R.S. Xu, R.A. Gladdy, J.A. McCart, A. Govindarajan, C.J. Swallow

Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer
P.M. Cheon

Oncology Education for Canadian Internal Medicine Residents: The Value of Participating in a Medical Oncology Elective Rotation
N.A. Nixon, H. Lim, C. Elser, Y.-J. Ko, R. Lee-Ying, V.C. Tam

Baseline Edmonton Symptom Assessment Scale (ESAS) and Survival in Metastatic Renal Cell Carcinoma (mRCC)
J. Graham, J. Gingerich, P. Lambert, A. Alamri, P. Czaykowski

Overcoming resistance in a BRAFv600e mutant adenocarcinoma of the lung
T. Schmid, M. Buess

The evolution of biosimilars in oncology, with a focus on trastuzumab
N.A. Nixon, M. Hannouf, S. Verma

Ode to my Oncologist
C. Heykoop

Provincial discordance and cancer drug funding – understanding why
A. Srikanthan, N. Penner, K. Chan, M. Sabharwal, A. Grill

Medical Oncology Workload in Canada: Infrastructure, Supports, and Delivery of Clinical Care
A. Fundytus, W. Hopman, N. Hammad, J. Biagi, R. Sullivan, V. Vanderpuye, B. Seruga, G. Lopes, M. Sengar, M. Brundage, C. Booth

Hormone receptor positive HER2-negative metastatic breast cancer: redrawing the lines
A. Matutino, A.A. Joy, C. Brezden-Masley, S. Chia, S. Verma

Harmonization of PD-L1 Testing in Oncology: Canadian Pathology Perspective
D. Ionescu, M. Downes, A. Christofides, M.-S. Tsao

Oncology Education for Internal Medicine Residents: A Call for Action!
T. Younis, B. Colwell